Skip to main content
SpringerLink
Log in

Endocrine AEs during nivolumab therapy biomarker of response?

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Maeda T, et al. Development of endocrine immune-related adverse events and improved survival in advanced melanoma patients treated with nivolumab monotherapy. European Journal of Cancer 115: 13-16, 10 May 2019. Available from: URL: http://doi.org/10.1016/j.ejca.2019.04.005

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Endocrine AEs during nivolumab therapy biomarker of response?. Reactions Weekly 1754, 7 (2019). https://doi.org/10.1007/s40278-019-62240-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-019-62240-2

Search

Navigation